Gorlin-Chaudhry-Moss syndrome (GCM syndrome) is a genetic disorder that belongs to a group of disorders associated with DNA repair system failures, observed in patients both in the case of hereditary predisposition and spontaneous mutations. The main mechanism of action of the syndrome is associated with excessive activity of pathogenetic processes, which leads to the formation of various tumors, primarily basal cell carcinomas of the skin, as well as possible defects in the development of facial structures, pathologies in the skeletal system and other organs. GCM syndrome is often diagnosed at a young age and may be associated with an increased risk of developing certain carcinomas.
History of the disease and interesting historical facts
The first mention of Gorlin syndrome occurred in 1894, when American dermatologist Robert Gorlin described signs characteristic of basal cell carcinoma and some facial skeletal abnormalities in young patients. In the 1960s, the study was continued, and a link was established between these characteristics and inherited genetic factors. Over time, the syndrome began to attract increasing interest in medical circles, which contributed to the identification of new clinical and molecular aspects of the disease. Important contributions to the study of the disease were made by scientists such as Choudhry and Moss, who revealed the link between the syndrome and mutations in the PTCH gene, which provided extensive opportunities for further research and understanding of the molecular pathogenesis of the disease.
Epidemiology
According to epidemiological studies, Gorlin-Chaudhry-Moss syndrome occurs with a frequency of approximately 1 in 57,000 births. The disease is observed in both males and females, although males may have more pronounced phenotypic symptoms. The disease is rare, but higher prevalence rates may be recorded in some populations. An "underdiagnosis" effect also exists, making the true figures likely higher than those reported. To some extent, the syndrome may be underdiscovered in some countries due to insufficient awareness of specialists.
Genetic predisposition to this disease
Gorlin-Chaudhry-Moss syndrome has a clear genetic predisposition associated with mutations in the PTCH1 gene on chromosome 9q22.3. This gene encodes a protein that plays a key role in the Hedgehog pathway signaling responsible for cell proliferation and differentiation. Pathogenic mutations in this gene lead to dysregulation of the cell cycle and an increased risk of neoplastic transformation. In addition to PTCH1, some patients may also have mutations in the SUFU and PTCH2 genes, which may contribute to the clinical picture of the syndrome. Genetic testing is a tool to confirm the diagnosis and trace the family.
Risk factors for the development of this disease
The risk of developing Gorlin-Chaudhry-Moss syndrome increases with a family history of the disease. This is due to the autosomal dominant mechanism of inheritance. I would also like to note the following factors that predispose it:
- Heredity: presence of parents with this mutation;
- Parental age: increased risk in mothers over 35 years of age;
- Etiological factors: exposure to certain chemicals and radiation.
- Solar irradiation: extremes of exposure to ultraviolet radiation background, which play a role in modulating cellular metabolism.
Diagnosis of this disease
Diagnosis of Gorlin-Chaudhry-Moss syndrome is based on a combination of clinical manifestations and molecular genetic technologies. The main symptoms include multiple basal cell carcinomas, cysts, dental defects, and facial abnormalities. Laboratory tests may include blood tests to detect mutations in genes associated with the disease. Radiological tests, such as X-rays and MRIs, are used to detect abnormalities in bone structure, especially in the skull and jaw. Differential diagnosis should be made with other inherited syndromes, such as Li-Fraumeni syndrome or Costen syndrome.
Treatment
Treatment of Gorlin-Chaudhry-Moss syndrome is multi-stage and includes several areas. General therapy involves regular monitoring of the patient's condition and early detection of tumors. Surgery is used to remove basal cell carcinomas and other formations. Pharmacological treatment may include the use of Hedgehog inhibitors, such as Vismed (Sonidogib), which can significantly reduce the development and progression of tumors. Other treatments may include photodynamic therapy and cryotherapy for the treatment of small skin lesions.
List of medications used to treat this disease
- Sonidogib (vismed);
- Ketoconazole (an antifungal drug with antitumor properties);
- Creams with 5-fluorouracil;
- Hedgehog channel inhibitors;
- Medicines for pain syndrome therapy.
Disease monitoring
Monitoring of patients with HCM syndrome includes regular examinations by a dermatologist, oncologist and dentist for early detection of tumors and dental anomalies. Health monitoring is carried out through annual examinations and imaging. The prognosis for patients with the syndrome is generally favorable, provided that diagnosis and treatment are timely. However, it should be noted that there is a high risk of developing secondary tumors, special attention should be paid to possible complications associated with damage to various body systems.
Age-related features of the disease
Gorlin-Chaudry-Moss syndrome can manifest at various ages, but most often symptoms begin in childhood or adolescence. In young children, multiple cysts are typical, while in adolescents and adults, a high incidence of basal cell carcinomas may be observed. In older people, attention is paid to prevention and early diagnosis, since the risk of tumor growth and progression increases.
Questions and Answers
- What are the main symptoms of Gorlin-Chaudhry-Moss syndrome? Symptoms include multiple basal cell carcinomas of the skin, cysts in the skin and facial structure, dental defects and skeletal abnormalities.
- How is the disease diagnosed? Diagnosis is made through clinical examinations, laboratory tests to detect mutations, and radiological examination.
- What treatment is recommended for patients with the syndrome? Treatment includes surgical removal of the lesions, use of Hedgehog inhibitors and regular monitoring of the skin condition.
- What is the prognosis for patients with HCM syndrome? The prognosis is generally good with regular examination and early treatment, but there is a risk of developing secondary tumors.
- Are genetic tests available to check for the syndrome? Yes, genetic tests are available to detect mutations in the PTCH1 gene and other related genes.
Advice from Dr. Oleg Korzhikov on this disease: “It is important to remember about regular medical examinations with specialists, since early detection of anomalies can significantly improve the prognosis. It is important for me that patients understand that following the rules of sun protection and monitoring the condition of the skin can reduce the risk of new formations. Proper oral hygiene also plays a significant role in preventing dental anomalies. Try to visit the dentist at least twice a year.”
